Bio-Techne Corporation Brands
Learn about our life science and clinical diagnostic brands.
R&D Systems entered the field of biotechnology early, becoming the first company to commercially market the multifunctional cytokine TGF-beta 1. R&D Systems has since established itself as a developer and manufacturer of high-quality proteins and the world leader in immunoassays as well as a producer of antibodies, arrays, stem cell products, cell selection and detection products among other cell biology tools.
Novus Biologicals was founded in the summer of 1996 to license, produce and market antibodies to support niche and emerging areas of research. From Western blots on the kitchen table to a full lab and 200,000 plus antibodies and antibody-related products, we have come a long way from our niche antibody strategy. Novus is built on honesty, collaboration and strong relationships and will continue to provide quality tools to accelerate the bioscience research community.
Tocris is the leading supplier of novel, exclusive small molecules and peptides for life science research. Used in experiments to understand biological processes and diseases and as part of the initial drug-discovery process, Tocris life science reagents include receptor ligands, ion channel modulators, enzyme inhibitors, caged compounds, fluorescent probes, and screening libraries.
ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Their goal is to make protein analysis simpler, more quantitative and affordable. Their comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD technology is used in proprietary diagnostic tests for cancer management and to validate biomarkers for targeted therapeutic development.
Exosome Diagnostics, is a world leader in developing liquid biopsy-based diagnostics and empowers the world’s leading biopharma companies' biomarker discovery, translational research, and clinical trials through partnerships. ExosomeDx offers services using RNA, cell-free DNA, and proteins with their proprietary technology to explore and identify biomarkers. It is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. Exosome Diagnostics is a core provider to support advancement of patient care.